Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors

被引：4

作者：

Aghel, Nazanin ^{[1
,2
]}

Vila, Rocio C. Baro C. ^{[2
,3
]}

Lui, Michelle ^{[4
]}

Hillis, Christopher ^{[5
]}

Leong, Darryl P. P. ^{[1
,2
]}

机构：

[1] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Hamilton, ON, Canada

[3] Inst Cardiovasc Buenos Aires ICBA, Div Cardiol, Buenos Aires, Argentina

[4] Hamilton Hlth Sci, Hamilton, ON, Canada

[5] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

来源：

CURRENT CARDIOLOGY REPORTS | 2023年 / 25卷 / 9期

关键词：

Bruton's tyrosine kinase inhibitor; Atrial fibrillation; Cardio-Oncology; B-cell malignancies; Ibrutinib; Heart failure; CHRONIC LYMPHOCYTIC-LEUKEMIA; CARDIOLOGY/AMERICAN HEART ASSOCIATION; MANTLE-CELL LYMPHOMA; TERM-FOLLOW-UP; ATRIAL-FIBRILLATION; IBRUTINIB USE; AMERICAN-COLLEGE; TREATMENT-NAIVE; TARGETING BTK; RISK;

D O I：

10.1007/s11886-023-01916-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of ReviewBruton's tyrosine kinase inhibitors (BTKis) have changed the treatment and prognosis of several B-cell malignancies. However, since the approval of the first BTKi, ibrutinib, reports of cardiovascular adverse events especially atrial fibrillation have arisen. In this review, we discuss the cardiovascular side effects of BTKis and the management of these toxicities in clinical practice.Recent FindingsBTKIs increase the risks of atrial fibrillation, bleeding, hypertension, heart failure, and potentially ventricular arrhythmia. Newer second and third-generation BTKis appear to have a lower risk of cardiovascular adverse events; however, long-term follow-up data are not available for these new BTKis.BTKis are an effective treatment for some B-cell malignancies; however, they can cause cardiovascular side effects. The best preventive strategies to minimize cardiovascular complications remain undefined. Currently, a practical approach for managing patients receiving BTKis includes the management of cardiovascular risk factors and side effects of BTKis to prevent interruption of cancer treatment.

引用

页码：941 / 958

页数：18

共 76 条

[1] Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study [J].

Abdel-Qadir, Husam ;

Sabrie, Nasruddin ;

Leong, Darryl ;

Pang, Andrea ;

Austin, Peter C. ;

Prica, Anca ;

Nanthakumar, Kumaraswamy ;

Calvillo-Arguelles, Oscar ;

Lee, Douglas S. ;

Thavendiranathan, Paaladinesh .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) :3453-+

[2] BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies [J].

Alu, Aqu ;

Lei, Hong ;

Han, Xuejiao ;

Wei, Yuquan ;

Wei, Xiawei .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)

[3] The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation [J].

Andrade, Jason G. ;

Aguilar, Martin ;

Atzema, Clare ;

Bell, Alan ;

Cairns, John A. ;

Cheung, Christopher C. ;

Cox, Jafna L. ;

Dorian, Paul ;

Gladstone, David J. ;

Healey, Jeff S. ;

Khairy, Paul ;

Leblanc, Kori ;

McMurtry, M. Sean ;

Mitchell, L. Brent ;

Nair, Girish M. ;

Nattel, Stanley ;

Parkash, Ratika ;

Pilote, Louise ;

Sandhu, Roopinder K. ;

Sarrazin, Jean-Francois ;

Sharma, Mukul ;

Skanes, Allan C. ;

Talajic, Mario ;

Tsang, Teresa S. M. ;

Verma, Atul ;

Verma, Subodh ;

Whitlock, Richard ;

Wyse, D. George ;

Macle, Laurent .

CANADIAN JOURNAL OF CARDIOLOGY, 2020, 36 (12) :1847-1948

[4]

[Anonymous], Highlights of prescribing information - Victoza

[5] BRUTON TYROSINE KINASE IS TYROSINE-PHOSPHORYLATED AND ACTIVATED IN PRE-B LYMPHOCYTES AND RECEPTOR-LIGATED B-CELLS [J].

AOKI, Y ;

ISSELBACHER, KJ ;

PILLAI, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (22) :10606-10609

[6] Ibrutinib: a paradigm shift in management of CLL [J].

Badar, Talha ;

Burger, Jan A. ;

Wierda, William G. ;

O'Brien, Susan .

EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (06) :705-717

[7] Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia [J].

Barr, Paul M. ;

Owen, Carolyn ;

Robak, Tadeusz ;

Tedeschi, Alessandra ;

Bairey, Osnat ;

Burger, Jan A. ;

Hillmen, Peter ;

Coutre, Steve E. ;

Dearden, Claire ;

Grosicki, Sebastian ;

McCarthy, Helen ;

Li, Jian-Yong ;

Offner, Fritz ;

Moreno, Carol ;

Zhou, Cathy ;

Hsu, Emily ;

Szoke, Anita ;

Kipps, Thomas J. ;

Ghia, Paolo .

BLOOD ADVANCES, 2022, 6 (11) :3440-3450

[8]

Berti Sergio, 2022, JACC Case Rep, V4, P755, DOI 10.1016/j.jaccas.2022.04.015

[9] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Brown, J. R. ;

Eichhorst, B. ;

Hillmen, P. ;

Jurczak, W. ;

Kazmierczak, M. ;

Lamanna, N. ;

O'Brien, S. M. ;

Tam, C. S. ;

Qiu, L. ;

Zhou, K. ;

Simkovic, M. ;

Mayer, J. ;

Gillespie-Twardy, A. ;

Ferrajoli, A. ;

Ganly, P. S. ;

Weinkove, R. ;

Grosicki, S. ;

Mital, A. ;

Robak, T. ;

Osterborg, A. ;

Yimer, H. A. ;

Salmi, T. ;

Wang, M. -D. -Y. ;

Fu, L. ;

Li, J. ;

Wu, K. ;

Cohen, A. ;

Shadman, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04) :319-332

[10] Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients [J].

Brown, Jennifer R. ;

Byrd, John C. ;

Ghia, Paolo ;

Sharman, Jeff P. ;

Hillmen, Peter ;

Stephens, Deborah M. ;

Sun, Clare ;

Jurczak, Wojciech ;

Pagel, John M. ;

Ferrajoli, Alessandra ;

Patel, Priti ;

Tao, Lin ;

Kuptsova-Clarkson, Nataliya ;

Moslehi, Javid ;

Furman, Richard R. .

HAEMATOLOGICA, 2022, 107 (06) :1335-1346

← 1 2 3 4 5 6 7 8 →